Firms may find it ‘difficult’ to co-market combined Covid-19 drugs, says analyst
Remdesivir is marketed by US pharma firm Gilead Sciences, while baricitinib is sold by Eli Lilly
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more